Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Reiterates Outperform on Design Therapeutics, Maintains $24 Price Target

RBC Capital analyst Leonid Timashev reiterates Design Therapeutics (NASDAQ:DSGN) with a Outperform and maintains $24 price target.
byBenzinga Newsdesk
March 15, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

RBC Capital analyst Leonid Timashev reiterates Design Therapeutics (NASDAQ:DSGN) with a Outperform and maintains $24 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts